Allopurinol in Advanced CKD — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Yes Allopurinol can be used in CKD starting at a low dose (50-100 mg daily in CKD 4-5) and titrated cautiously with close monitoring; the target serum urate remains the same
Both NICE 2022 and ACR 2020 guidelines support Allopurinol use in CKD including advanced stages. The starting dose should be lower (50-100 mg in CKD stage 4-5 vs 100 mg in normal renal function) with slower uptitration (monthly increments guided by serum urate and tolerability). The serum urate target remains the same (<360 micromol/L). Evidence from Stamp LK et al 2017 demonstrated that cautious dose escalation above creatinine clearance-based recommendations is safe and effective. Febuxostat is an alternative that requires less dose adjustment in mild-moderate CKD. Uricosurics are ineffective in advanced CKD.
Reference: NICE NG219 (2022) gout; ACR 2020 gout; Stamp LK et al 2017 Allopurinol in CKD